http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112915198-B

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y302-01017
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-47
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-47
filingDate 2016-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2022-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2022-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-112915198-B
titleOfInvention An ointment containing lysozyme for treating psoriasis
abstract The invention relates to a pharmaceutical composition for treating psoriasis, wherein the weight ratio of lysozyme to emodin as active ingredients is (1:10) - (10: 1). Compared with the common western medicine preparation, the lysozyme preparation provided by the invention has the advantages that the preparation method is simple, the compatibility is reasonable, the two active ingredients can generate a synergistic interaction effect while exerting respective effects, and the psoriasis is remarkably treated. The lysozyme and the emodin are natural in source, safe and non-toxic, and have no side effect; because the pharmaceutical composition contains no western medicine components, the medicine has no drug resistance.
priorityDate 2016-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP51728
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9T1T5
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ7Y2C0
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9T1X2
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3220
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP33486
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ37896
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP13559
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP19385
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP19386
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP78285
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP15057
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP07540
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419477623
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP09963
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ6XQ98
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ556F2
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP00720
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP68920
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP68921
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO64362
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO80288
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ86AA1
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP62692
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP62693
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO80292
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP27359
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9ZXB7
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP10439
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP76159
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ37875
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP11187

Total number of triples: 52.